At IVOQA we have early diagnosis tests that detect the possibility of suffering from colon cancer up to 10 or 15 years before the first symptom.
Colon cancer is one of the leading causes of death from cancer worldwide. Detecting this disease in its early stages is crucial to improving survival rates. Our colon cancer test offers an innovative, non-invasive solution for early detection.
The Mirnax stool sample test uses specific genetic biomarkers present in stool to identify polyps and adenomas with a high potential to develop into cancer.
This method allows colon cancer to be detected up to 10-15 years before the first symptoms appear.
This test, therefore, identifies the presence of colon tumors but also detects even the presence of small polyps in the colon.
Detects colon cancer in its early stages, significantly improving the chances of successful treatment.
Unlike colonoscopy, our test does not require invasive procedures or bowel preparation.
Provides fast and reliable results within a week to ten days, allowing for early intervention if necessary.
Mirnax Biosens, a Spanish biotechnology company focused on molecular diagnostics, has developed a test that can identify the possibility of suffering from this cancer many years in advance, with the aim of preventing patients from entering more advanced stages and implementing a prevention plan as early as possible.
This type of cancer usually begins with the formation of polyps in the colon, which are accumulations of cells in the epithelial lining that initially do not cause any symptoms. Although most of these polyps are harmless, a small percentage may progress to invasive cancer if not detected early. A thorough understanding of polyps and their relationship to CRC is crucial to develop effective prevention and screening strategies, which in turn can improve clinical outcomes and quality of life for patients.
Polyps in the colon develop due to a failure of the apoptosis mechanism, which is the natural process of programmed cell death.
This failure causes uncontrolled cell growth that can lead to the formation of malignant tumors.
Although it is estimated that only 5% of polyps develop into malignant tumors, they account for more than 95% of cases of cancer in the large intestine.
Since progression from polyp to CRC is a gradual process involving multiple steps with genetic and epigenetic alterations that affect the regulation of genes responsible for essential cellular processes, the method developed by MiRNAX Biosens identifies the operators that are activated as cells undergo mutations and transform from normal cells to cancer cells.
MIRNAX sensitivity:
The predictive value certified by the British notifying body UKAS for the sample volume specified in the IFU is 97%, with a specificity of over 99%. In other words, they have been certified by the British Notified Body (UKAS) to comply with the requirements set by the different governing bodies registered in the United States and endorsing that the biomarkers detected in each case have a minimum predictive value of 97% under routine conditions.
Colonoscopy Sensitivity:
Sensitivity for adenomas or colorectal cancer (CRC) of 10 mm or larger detected by colonoscopy is 84%, with a specificity of 85%. For adenomas 6 mm or larger, the sensitivity is 70%, with a specificity of 86%. –> REF: Johnson CD, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N. Engl. J. Med. 2008;359:1207-1217. doi: 10.1056/NEJMoa0800996.
At this time, insurers do not cover the test.
Yes, one of the indications for this test is for people with a family history of colon cancer. As a high-risk patient, this test can help avoid the need for an annual or biannual colonoscopy, as long as no polyps or tumors are detected.
No preparation of any kind is required.
After a consultation with our specialists, who will determine if the test is appropriate for your case, you can purchase it at IVOQA. You can bring the sample when you have it or, by means of a QR code, we can arrange for it to be picked up at your home. You can make an appointment here.
The test should not be compared with colonoscopy, as the latter is neither a screening tool nor a tool for hyper-early diagnosis. Colonoscopy is considered the gold standard for the visual detection of colorectal cancer, as it not only identifies polyps and lesions, but also allows biopsies and, above all, removal of polyps during the same procedure.
Therefore, if the Mirnax test is positive, it will be necessary to consult with the physician or primary care nurse to assess the indication for a confirmatory test by means of a screening colonoscopy.
The result of the colonoscopy will determine the periodicity with which subsequent follow-up colonoscopies should be performed or the moment of re-entry into the program by means of a new test, applying an interval of 6 to 24 months for the screening to be effective.
